Details
Stereochemistry | EPIMERIC |
Molecular Formula | C32H48BF5O4S |
Molecular Weight | 634.589 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]3([H])C4=CC=C(C=C4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@@]23[H])B(O)O
InChI
InChIKey=FIAYIYKWRBIBQG-GDWZZRAASA-N
InChI=1S/C32H48BF5O4S/c1-30-17-15-26-25-12-11-24(33(40)41)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-43(42)19-9-16-31(34,35)32(36,37)38/h11-12,21-22,26-29,39-41H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,43?/m1/s1
Molecular Formula | C32H48BF5O4S |
Molecular Weight | 634.589 |
Charge | 0 |
Count |
|
Stereochemistry | EPIMERIC |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:56:34 GMT 2023
by
admin
on
Sat Dec 16 16:56:34 GMT 2023
|
Record UNII |
E35ZN95LMT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
E35ZN95LMT
Created by
admin on Sat Dec 16 16:56:34 GMT 2023 , Edited by admin on Sat Dec 16 16:56:34 GMT 2023
|
PRIMARY | |||
|
ZB716
Created by
admin on Sat Dec 16 16:56:34 GMT 2023 , Edited by admin on Sat Dec 16 16:56:34 GMT 2023
|
PRIMARY | |||
|
1853279-29-4
Created by
admin on Sat Dec 16 16:56:34 GMT 2023 , Edited by admin on Sat Dec 16 16:56:34 GMT 2023
|
PRIMARY | |||
|
DTXSID601107524
Created by
admin on Sat Dec 16 16:56:34 GMT 2023 , Edited by admin on Sat Dec 16 16:56:34 GMT 2023
|
PRIMARY | |||
|
126480615
Created by
admin on Sat Dec 16 16:56:34 GMT 2023 , Edited by admin on Sat Dec 16 16:56:34 GMT 2023
|
PRIMARY | |||
|
C179265
Created by
admin on Sat Dec 16 16:56:34 GMT 2023 , Edited by admin on Sat Dec 16 16:56:34 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
In vitro and in vivo pharmacological studies of ZB716 demonstrate it is a pure antagonist of the
ER. It binds to the ER and degrades the protein in a dose-dependent manner.
IN-VITRO, IN-VIVO
|
||
|
TARGET->DEGRADER |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|